BioCentury on BioBusiness,
Almirall COPD assets give AZ time for respiratory pipeline to mature
Related tables, figures and sidebars
Monday, August 18, 2014
plc's acquisition of Almirall
S.A.'s respiratory assets should buy the pharma time while
its respiratory pipeline matures. The deal not only gives AstraZeneca a faster
route to market in the COPD combination therapy race - moving it into third
place behind GlaxoSmithKline
plc and Novartis
AG - but also gives AZ a greater range of choices for
combination therapies in two device formats in a disease space where patient
preference is important.
therapies lead the line in AstraZeneca's respiratory franchise, but the
long-term goal is to complement them with biologics for more severe disease -
and AZ has one of the broadest pipelines of respiratory biologics in the
industry, with two biologics in Phase III testing and a pair in Phase II.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]